Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1990-7-11
|
| pubmed:abstractText |
Over the past few years controversy has continued as to whether alkylating agents such as cyclophosphamide or chlorambucil are as effective as cisplatin in advanced ovarian cancer. Arguments have also been put forward against the use of combination chemotherapy, which is clearly more toxic than single-agent treatment and is probably no more effective than a single-agent platinum compound except in terms of producing a higher response rate. Certainly survival is not improved.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0344-5704
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26 Suppl
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S48-50
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2189595-Antineoplastic Agents,
pubmed-meshheading:2189595-Carboplatin,
pubmed-meshheading:2189595-Clinical Trials as Topic,
pubmed-meshheading:2189595-Drug Evaluation,
pubmed-meshheading:2189595-Female,
pubmed-meshheading:2189595-Humans,
pubmed-meshheading:2189595-Ifosfamide,
pubmed-meshheading:2189595-Organoplatinum Compounds,
pubmed-meshheading:2189595-Ovarian Neoplasms,
pubmed-meshheading:2189595-Pilot Projects,
pubmed-meshheading:2189595-Random Allocation,
pubmed-meshheading:2189595-Survival Rate
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group.
|
| pubmed:affiliation |
Royal Marsden Hospital, London, United Kingdom.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|